EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY 4.0

Continuous Infusion of the CXCR4 Antagonist Plerixafor for WHIM Syndrome

David H McDermott, Shamik Majumdar, Daniel Velez, Elena Cho, Zhanzhou Li, Ji-Liang Gao, Megan C Grieco, Monica G Lawrence, Susana L Silva, Leslie A Castelo-Soccio, Dean Follmann, Philip M Murphy

Journal of Clinical Immunology · 29.03.2026 · 46 (1)

DOI: 10.1007/s10875-026-02010-4 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Immunology, online erschienen am 29.03.2026. Verfasst von David H McDermott und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, USA. Hauptthemen laut MEDLINE: Receptors, CXCR4, Warts, Heterocyclic Compounds, Primary Immunodeficiency Diseases. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) syndrome is an ultrarare inborn error of immunity caused by heterozygous, hyperfunctional CXCR4 mutations that impede leukocyte egress from bone marrow, resulting in panleukopenia. The CXCR4 antagonist plerixafor (AMD3100, Mozobil) durably reverses panleukopenia and in most WHIM patients also induces wart regression; however, its short half-life requires twice daily injection.

Objective

The aim of this study was to assess the safety and efficacy of continuously infused plerixafor in patients with WHIM syndrome.

Methods

We conducted a Phase 1/2 pilot study of WHIM patients given plerixafor 0.02–0.08 mg/kg/d by continuous subcutaneous infusion for 1–2 years using an OmniPod insulin pump, and assessed compliance as well as effects on blood leukocyte counts, infections, chronic skin conditions and adverse events.

Results

Six patients were treated for a total of 6.3 patient-years; one patient dropped out early for personal reasons related to taking a new job. The drug infusion rate was adjusted to achieve a normal absolute lymphocyte count and an absolute neutrophil count > 500 cells/µl in all patients. An average of 2.1 infections/patient-year occurred (range 0–4). Treatment of two infections involved brief hospitalization. On plerixafor, partial wart regression occurred in 3 of 4 patients, a single molluscum contagiosum infection regressed and a chronic post-Mohs surgical wound epithelialized. There were 3 serious adverse events, but none was attributable to the treatment. All patients preferred pump administration over syringe injection.

Conclusion

In WHIM patients a continuous infusion pump may be a convenient, safe and potentially effective means of delivering plerixafor chronically to correct panleukopenia and to improve chronic skin conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CXCR4WartsHeterocyclic CompoundsPrimary Immunodeficiency DiseasesImmunologic Deficiency SyndromesHumansCyclamsBenzylaminesFemaleMaleAdultTreatment OutcomePilot ProjectsMiddle AgedAdolescentYoung Adult

Stichwörter der Autor:innen

Chemokine receptorClinical trialImmunodeficiencyLymphopeniaNeutropenia

Substanzen

Receptors, CXCR4CyclamsBenzylaminesplerixaforHeterocyclic CompoundsCXCR4 protein, human

Autor:innen und Institutionen

  • Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, USA.
  • Biostatics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Axle Informatics, Bethesda, MD, USA.
  • Division of Asthma, Allergy and Immunology, University of Virginia School of Medicine, Charlottesville, VA, USA.
  • Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Serviço de Imunoalergologia, Unidade Local de Saúde de Santa Maria, Lisbon, Portugal.

Förderung

  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

McDermott, D. H., Majumdar, S., Velez, D., Cho, E., Li, Z., Gao, J. L., Grieco, M. C., Lawrence, M. G., Silva, S. L., Castelo-Soccio, L. A., Follmann, D., & Murphy, P. M. (2026). Continuous Infusion of the CXCR4 Antagonist Plerixafor for WHIM Syndrome. Journal of Clinical Immunology, 46(1). https://doi.org/10.1007/s10875-026-02010-4

Vancouver

McDermott DH, Majumdar S, Velez D, Cho E, Li Z, Gao JL, et al. Continuous Infusion of the CXCR4 Antagonist Plerixafor for WHIM Syndrome. Journal of Clinical Immunology. 2026;46(1). doi:10.1007/s10875-026-02010-4

BibTeX
@article{McDermott2026,
  author = {McDermott, David H and Majumdar, Shamik and Velez, Daniel and Cho, Elena and Li, Zhanzhou and Gao, Ji-Liang and Grieco, Megan C and Lawrence, Monica G and Silva, Susana L and Castelo-Soccio, Leslie A and Follmann, Dean and Murphy, Philip M},
  title = {Continuous Infusion of the CXCR4 Antagonist Plerixafor for WHIM Syndrome},
  journal = {Journal of Clinical Immunology},
  year = {2026},
  volume = {46},
  number = {1},
  doi = {10.1007/s10875-026-02010-4}
}
Kostenlos starten →